Compare · GILD vs MRK
GILD vs MRK
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GILD focuses on Biotechnology: Biological Products (No Diagnostic Substances), while MRK focuses on Biotechnology: Pharmaceutical Preparations.
- MRK is the larger of the two at $356.01B, about 2.0x GILD ($179.47B).
- Over the past year, GILD is up 27.3% and MRK is up 57.1% - MRK leads by 29.8 points.
- MRK has been more active in the news (13 items in the past 4 weeks vs 5 for GILD).
- Both have 25 recent analyst ratings on file.
- Company
- Gilead Sciences Inc.
- Merck & Company Inc.
- Price
- $144.59-0.09%
- $139.51-3.32%
- Market cap
- $179.47B
- $356.01B
- 1M return
- -4.33%
- -8.41%
- 1Y return
- +27.30%
- +57.10%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1992
- News (4w)
- 5
- 13
- Recent ratings
- 25
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest GILD
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
- Chief Medical Officer Berger Dietmar converted options into 533 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 1% to 19,522 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 1% to 119,684 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 590 shares and covered exercise/tax liability with 285 shares, increasing direct ownership by 4% to 8,759 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,780 shares and covered exercise/tax liability with 4,230 shares, increasing direct ownership by 0.79% to 581,683 units (SEC Form 4)
Latest MRK
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
- CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program
- Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
- Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
- Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
- U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
- Merck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul Trembles